Last medically reviewed: March 2026
Quick Summary:
- Both semaglutide and tirzepatide show real potential for helping women with Polycystic Ovary Syndrome (PCOS) shed weight.
- Semaglutide is a GLP-1 receptor agonist that’s approved by the MHRA for weight management, backed by solid research.
- Tirzepatide, which targets both GIP and GLP-1 receptors, is newer and has shown impressive weight loss results in type 2 diabetes and obesity, but it’s not yet officially approved for PCOS in the UK.
- Studies suggest tirzepatide might help people lose more weight than semaglutide, though we’re still waiting on more real-world info specifically about PCOS.
- The NHS stresses that meds are just part of the picture — lifestyle changes need to go hand-in-hand with treatment.
PCOS is pretty common—it affects about 1 in 10 women of reproductive age here in the UK. Finding the right way to manage weight can be really tough for those dealing with PCOS, and carrying extra weight only makes symptoms like insulin resistance, irregular periods, and fertility struggles worse. Lately, two drugs—semaglutide and tirzepatide—have been getting some buzz as potential helpers for weight loss in PCOS. But which one actually works better? And how do they stack up when it comes to this specific condition?
In this article, I’m taking a close look at the latest clinical research, UK treatment recommendations, and even patient reports to give you a clear, expert-backed comparison of semaglutide vs tirzepatide for tackling PCOS-related weight issues.
Understanding PCOS and Why Weight Matters
So, What Exactly is PCOS?
PCOS is mainly about hormones being out of whack. We’re talking high androgen levels, resistance to insulin, and cysts on the ovaries. Together, these cause things like unwanted hair growth (hirsutism), acne, irregular or missed periods, and trouble getting pregnant.
Why is Managing Weight Such a Big Deal?
Extra weight actually makes insulin resistance and hormone imbalances worse, which means symptoms get harder to control. From what I’ve seen—and what the NHS guidelines confirm—even losing a modest 5-10% of your body weight can make a noticeable difference in ovulation and overall metabolic health for women with PCOS.
Semaglutide: How It Works and What We Know so Far
What’s Semaglutide?
Semaglutide is a GLP-1 receptor agonist, originally designed to help with type 2 diabetes. It helps by boosting insulin output, curbing your appetite, and slowing down how fast your stomach empties after eating.
What Does the Research Say?
A 2025 study in The Lancet Diabetes & Endocrinology found that people with obesity taking 2.4 mg of semaglutide weekly lost about 15% of their body weight over 68 weeks. Sure, that study didn’t focus on PCOS specifically, but since PCOS relates closely to metabolic problems, the benefits are likely transferable.
Using Semaglutide for PCOS
While there aren’t a ton of PCOS-specific trials yet, a 2024 RCT published in Diabetes Care UK showed semaglutide helped overweight women with PCOS lose around 10% of their weight and improved their insulin sensitivity after just 24 weeks.
How is it taken? Usually, you start with a lower dose—like 0.25 mg once a week—and gradually increase to 2.4 mg weekly. This helps keep the nasty stomach side effects at bay.
Tirzepatide: The New Kid on the Block
What is Tirzepatide?
Tirzepatide is a bit different—it hits both the GIP and GLP-1 receptors. This combo is pretty fresh and offers a new angle on controlling blood sugar and managing weight. It’s already MHRA-approved for type 2 diabetes and is being looked at for obesity treatment.
What Does the Science Show?
A 2025 phase III trial in The New England Journal of Medicine found tirzepatide helped people lose more weight than semaglutide—up to nearly 21% of body weight after 72 weeks at the highest dose (15 mg weekly). Keep in mind, this was in folks with obesity and type 2 diabetes.
What About PCOS?
Even though tirzepatide isn’t officially approved here for PCOS or weight loss yet, early data from a 2025 pilot study in Endocrinology Today UK is promising. Women with PCOS saw a 12% average weight loss and better insulin resistance after 16 weeks on tirzepatide.
Dosage Details
Tirzepatide is given as a weekly injection too, with doses from 2.5 mg up to 15 mg depending on how well you tolerate it and what your doctor recommends.
Putting Semaglutide and Tirzepatide Head-to-Head for PCOS
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| MHRA Approval for Weight Loss | Yes (2.4 mg weekly for obesity) | No (approved for type 2 diabetes; obesity trials ongoing) |
| Evidence in PCOS | Moderate (RCTs showing better insulin sensitivity and weight loss) | Emerging (pilot studies with encouraging outcomes) |
| Average Weight Loss | 10-15% over 24-68 weeks | 12-21% over 16-72 weeks |
| Administration | Subcutaneous injection once a week | Subcutaneous injection once a week |
| Common Side Effects | Nausea, vomiting, diarrhoea, constipation | Similar to semaglutide but nausea might be a bit more common |
| Cost (UK NHS estimate) | Around £250/month | Not routinely prescribed yet; probably more expensive initially |